~~<i id='79A17CC232'><strike id='79A17CC232'><tt id='79A17CC232'><pre id='79A17CC232'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

leisure time

author：explore 2025-09-03 03:46:49 - browse：56457

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Intellia reports positive results for its CRISPR

knowledge

entertainment

focus

knowledge

courtesyIonisPharmaceuticalsIonisPharmaceuticals,aCaliforniacompanythatpioneeredawholeclassofRNA-tar

WSS

See how much Covid

Cord blood banking comes at a high cost to babies

How the Dana

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Health tech startups drop sharply from 2021 highs

Medicare drug price negotiation program allowed for now

knowledge

leisure time

knowledge

In Memoriam: Notable people who died in 2023

How to increase colonoscopy rates? Looks like an AI can help

Drug repurposing or repositioning? The language matters

Woman returns to dialysis after doctors remove transplanted pig kidney

New air purifier tech could be key to improving indoor air quality

Let's speed up science by embracing open access publishing

Continuity nursing helped my family in our darkest PICU moments

Listen: Who gets the credit for GLP

Novavax promises a turnaround & Lilly roils the obesity market

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

knowledge

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Cord blood banking comes at a high cost to babies

Cigna to pay $172 million to settle Medicare Advantage fraud probe

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Cigna to pay $172 million to settle Medicare Advantage fraud probe

FDA seeks to regulate lab

knowledge

entertainment

focus

knowledge